[go: up one dir, main page]

MX2017003808A - Una combinacion de quinurenina y celulas presentadoras de antigeno (apc) como productos terapeuticos y metodos para uso en modulacion inmunitaria. - Google Patents

Una combinacion de quinurenina y celulas presentadoras de antigeno (apc) como productos terapeuticos y metodos para uso en modulacion inmunitaria.

Info

Publication number
MX2017003808A
MX2017003808A MX2017003808A MX2017003808A MX2017003808A MX 2017003808 A MX2017003808 A MX 2017003808A MX 2017003808 A MX2017003808 A MX 2017003808A MX 2017003808 A MX2017003808 A MX 2017003808A MX 2017003808 A MX2017003808 A MX 2017003808A
Authority
MX
Mexico
Prior art keywords
apc
presenting cells
antigen presenting
quinurenine
methods
Prior art date
Application number
MX2017003808A
Other languages
English (en)
Other versions
MX386164B (es
Inventor
Ghahary Aziz
B Jalili Reza
T Kilani Ruhangiz
Li Yunyuan
Original Assignee
Univ British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ British Columbia filed Critical Univ British Columbia
Publication of MX2017003808A publication Critical patent/MX2017003808A/es
Publication of MX386164B publication Critical patent/MX386164B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/33—Fibroblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Cosmetics (AREA)

Abstract

La invención proporciona combinaciones de quinurenina y células presentadoras de antígeno (APC) para modular tolerancia inmunitaria, en donde las combinaciones se pueden usar para modular una respuesta inmunitaria, que puede ser de uso en el tratamiento de diabetes tipo I (TID) o alopecia areata (AA) También se proporcionan usos de quinurenina y células presentadoras de antígeno (APC) como un modulador inmunitario para el tratamiento de TID o AA.
MX2017003808A 2014-09-26 2015-09-25 Una combinación de quinurenina y células presentadoras de antígeno (apc) como productos terapéuticos y métodos para uso en modulación inmunitaria. MX386164B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462055823P 2014-09-26 2014-09-26
US201462087156P 2014-12-03 2014-12-03
PCT/CA2015/000506 WO2016044922A1 (en) 2014-09-26 2015-09-25 A combination of kynurenine and antigen presenting cells (apc) as therapeutics and methods for their use in immune modulation

Publications (2)

Publication Number Publication Date
MX2017003808A true MX2017003808A (es) 2017-12-15
MX386164B MX386164B (es) 2025-03-18

Family

ID=55579987

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017003808A MX386164B (es) 2014-09-26 2015-09-25 Una combinación de quinurenina y células presentadoras de antígeno (apc) como productos terapéuticos y métodos para uso en modulación inmunitaria.

Country Status (14)

Country Link
US (2) US20170209401A1 (es)
EP (1) EP3197466B1 (es)
JP (1) JP6898228B2 (es)
AU (1) AU2015321365B2 (es)
CA (1) CA2962655C (es)
CY (1) CY1124162T1 (es)
DK (1) DK3197466T3 (es)
ES (1) ES2867301T3 (es)
HU (1) HUE054020T2 (es)
MX (1) MX386164B (es)
PL (1) PL3197466T3 (es)
PT (1) PT3197466T (es)
RU (1) RU2727573C2 (es)
WO (1) WO2016044922A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190201360A1 (en) 2016-08-31 2019-07-04 Ampio Pharmaceuticals, Inc. Treatment of disease with n-acetyl kynurenine
US11712425B2 (en) 2018-03-14 2023-08-01 Albert Einstein College Of Medicine Immunoregulatory role of 3-OH-kynurenamine and uses thereof
WO2020093047A1 (en) 2018-11-04 2020-05-07 Figene, Llc Methods and compositions for treatment of type 1 diabetes using fibroblasts as facilitators of islet engraftment

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1265101B1 (it) * 1993-07-23 1996-10-30 Erba Carlo Spa Derivati dell'acido 2-ammino-4-fenil-4-osso butirrico
AU2002952834A0 (en) * 2002-09-16 2002-12-05 The Walter And Eliza Hall Institute Of Medical Research A method of treating an autoimmune disease
FR2849598B1 (fr) * 2003-01-07 2006-09-22 Merck Sante Sas Utilisation d'inhibiteurs de la kynurenine-3-hydroxylase pour le traitement du diabete, par augmentation du nombre de cellules des ilots de langerhans
EP2300828B1 (en) * 2008-07-01 2018-09-05 Genocea Biosciences Inc. Antigen screening system
CA2732806A1 (en) * 2008-08-04 2010-02-11 John Wityak Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
ITRM20080529A1 (it) * 2008-10-07 2010-04-08 Uni Degli Studi Perugia Uso della l-chinurenina e suoi derivati per la prevenzione ed il trattamento del diabete mellito di tipo 1.
JP2013535963A (ja) * 2010-07-15 2013-09-19 テクニオン リサーチ アンド ディベロップメント ファウンデーション リミテッド Ｍｈｃクラスｉｉと糖尿病関連自己抗原性ペプチドとの天然型複合体に対するｔ細胞受容体様特異性を有する単離された高親和性実体
WO2012136815A1 (en) * 2011-04-08 2012-10-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Culture medium and method for obtaining a population of tolerogenic dendritic cells
US8735359B2 (en) * 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes
GB201211120D0 (en) * 2012-06-22 2012-08-01 Bessede Alban Antagonist to an enzyme and/or a metabolite of the kynurenine pathway
JP2014111631A (ja) * 2014-01-31 2014-06-19 Tella Inc 樹状細胞の培養方法

Also Published As

Publication number Publication date
ES2867301T3 (es) 2021-10-20
RU2017114206A (ru) 2018-10-26
US20170209401A1 (en) 2017-07-27
AU2015321365B2 (en) 2021-05-20
EP3197466A1 (en) 2017-08-02
MX386164B (es) 2025-03-18
PL3197466T3 (pl) 2021-09-13
CA2962655A1 (en) 2016-03-31
DK3197466T3 (da) 2021-05-10
EP3197466B1 (en) 2021-02-17
EP3197466A4 (en) 2018-05-30
RU2727573C2 (ru) 2020-07-22
HUE054020T2 (hu) 2021-08-30
AU2015321365A1 (en) 2017-04-20
WO2016044922A1 (en) 2016-03-31
PT3197466T (pt) 2021-05-14
US20230414550A1 (en) 2023-12-28
RU2017114206A3 (es) 2019-04-30
JP6898228B2 (ja) 2021-07-07
CA2962655C (en) 2022-08-09
JP2017528508A (ja) 2017-09-28
CY1124162T1 (el) 2022-05-27

Similar Documents

Publication Publication Date Title
CY1123853T1 (el) Ρυθμιστες nrf2
CY1122227T1 (el) Ρυθμιση δραστικοτητας συμπληρωματος
EA201591474A1 (ru) Модуляторы метил-модифицирующих ферментов, композиции и их применение
CO2017002170A2 (es) Terapia de combinación para tratar un paramixovirus
EA201791007A2 (ru) Соединения и их применения для модуляции гемоглобина
ECSP18089579A (es) Moduladores de la vía de estrés integrada
EA201591426A1 (ru) Соединения и их применения для модуляции гемоглобина
MX2017002600A (es) Ligadores que modulan la estabilidad para usar con conjugados anticuerpo-farmaco.
EA201591432A1 (ru) Соединения и их применения для модуляции гемоглобина
ECSP17029218A (es) Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
MX2015003874A (es) Modulacion de ire1.
MX2021013837A (es) Enfoque de inmunoterapias de combinacion para el tratamiento del cancer.
PH12015501720B1 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
CO7151530A2 (es) Anticuerpos e inmunoconjugados anti-cd79b
MX2019008359A (es) Cadena j modificada.
MX369653B (es) Formulaciones de anticuerpos y proteinas.
EA201890329A1 (ru) СОЕДИНЕНИЯ В КАЧЕСТВЕ МОДУЛЯТОРОВ RORγ
CY1124761T1 (el) Ρυθμιστες της δραστικοτητας του συμπληρωματος
AU2018289493A1 (en) Methods for modulating regulatory T cells, regulatory B cells, and immune responses using modulators of the APRIL-TACI interaction
MX2016002574A (es) Nuevos moduladores del homologo 6 (sez6) y metodos de uso.
MX2023006416A (es) Anticuerpos, usos y metodos.
MA39835A (fr) Compositions et procédés de modulation de l'épissage du smn2 chez un patient
MX377774B (es) Formulaciones de proteinas.
MX2016003127A (es) Metodos de uso de células derivadas de tejido adiposo en la modulación de dolor y/o fibrosis.
MX2017000374A (es) Metodos y composiciones que regulan el crecimiento del pelo.